Michael Ehlers, Ascidian Therapeutics CEO (Photo: Kevin Trimmer)
June 18, 2024 07:00 AM EDT
Startups
Deals

Roche strikes neu­ro-fo­cused part­ner­ship with RNA ex­on edit­ing start­up, worth as much as $1.8B

Ryan Cross

Senior Science Correspondent

Roche has tapped a small Boston start­up for ac­cess to a sweep­ing form of RNA edit­ing that re­places large swathes of er­rant ge­net­ic code. Broad­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

The End­points 11 win­ners: Big bets on AI, new fron­tiers in edit­ing, a neu­ro re­nais­sance and Chi­nese chem­istry

Steve Davis leaves Aca­dia, re­placed by Bris­tol My­ers alum; For­mer J&J ex­ec to lead R&D at No­vavax

FDA ap­proves Dupix­ent in COPD, open­ing ‘next chap­ter’ for Sanofi and Re­gen­eron’s best­seller

No­vo Nordisk to de­crease some in­sulin pen man­u­fac­tur­ing, tran­si­tion sup­ply

FDA ap­proves Bris­tol My­ers and Karuna's schiz­o­phre­nia drug, in mile­stone for psy­chi­a­try

sponsored

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

A service from the Financial Times